北京福元医药股份有限公司关于股票交易异常波动的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of 20% over three consecutive trading days from July 31 to August 4, 2025, which is classified as an abnormal trading situation according to the Shanghai Stock Exchange rules [2][3]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 20% over three consecutive trading days, indicating abnormal trading activity [2][3]. - The company conducted a self-examination and confirmed that there were no undisclosed significant matters related to the stock price fluctuation [4]. Group 2: Company Operations and Major Events - The company's production and operational activities are reported to be normal, with no significant changes in the internal or external environment [4]. - The company confirmed that its controlling shareholder and actual controller have no undisclosed significant matters, including major asset restructuring or significant transactions [5]. Group 3: Market Sentiment and Media Reports - There has been increased market attention on the company's innovative drug business, particularly following the announcement of the clinical trial approval for its innovative drug FY101 [6]. - The company is currently in the I phase of clinical trials for FY101, with significant uncertainty regarding the trial's success [6]. Group 4: Other Relevant Matters - The company has not identified any other significant events that could impact its stock price, and there were no stock trades by directors, supervisors, or senior management during the abnormal trading period [7]. - The board of directors confirmed that there are no undisclosed matters that could significantly affect the company's stock price [11].